STOCK TITAN

Calliditas Therapeutics AB - CALT STOCK NEWS

Welcome to our dedicated news page for Calliditas Therapeutics AB (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics AB.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calliditas Therapeutics AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calliditas Therapeutics AB's position in the market.

Rhea-AI Summary
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée Aguiar-Lucander expressed excitement about the results and highlighted the upcoming presentation of data at the ERA EDTA symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Calliditas Therapeutics presented additional data analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024. The data showed consistent improvement in kidney function, reduced risk of kidney failure, and positive quality of life outcomes across different patient populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) announces its participation in key investor and industry conferences in April 2024, with top management presenting at various panels and offering one-on-one meetings. The company aims to showcase its expertise and engage with stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.6%
Tags
conferences
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) announces upcoming data presentations and a sponsored symposium at the ISN World Congress of Nephrology. The presentations will cover results from the Phase 3 NefIgArd trial with Nefecon in patients with IgA nephropathy, highlighting eGFR results, quality of life data, and benefits for patients with lower UPCR levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences
-
Rhea-AI Summary
Calliditas Therapeutics (CALT) receives a Notice of Allowance from the USPTO for a patent application related to cancer treatment with setanaxib and PD-1 inhibitors. The patent is anticipated to expire in 2038, providing extended protection for the global setanaxib franchise in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary
Everest Medicines' licensing partner, Calliditas Therapeutics, has received a seven-year orphan drug exclusivity period from the U.S. FDA for Nefecon®, a drug to reduce kidney function loss in adults with primary IgAN. This exclusivity covers all adult patients with primary IgAN at risk of disease progression, reflecting a significant clinical benefit on kidney function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) has received a seven-year orphan drug exclusivity period for TARPEYO®, expiring in December 2030, after obtaining full approval for a new indication to reduce kidney function loss in adults with primary IgAN. The exclusivity covers all adult patients with primary IgAN at risk of disease progression, reflecting a clinical benefit on kidney function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
none
-
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) announces CEO's participation in March 2024 conferences, including Carnegie Healthcare Seminar and Jefferies Biotech Summit. For more details, contact Head of IR & Sustainability, Åsa Hillsten.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) achieved full approval for TARPEYO in the US in 2023, marking a successful year. Net sales and operating income increased in Q4 2023 compared to Q4 2022. Cash decreased, but net sales and TARPEYO sales saw significant growth in 2023. The company anticipates revenue growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
Rhea-AI Summary
Calliditas to release Year-end report for January - December 2023 with CEO and CFO participation. Webcast and conference call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
Calliditas Therapeutics AB

Nasdaq:CALT

CALT Rankings

CALT Stock Data

545.72M
37.48M
3.18%
0.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Sweden
Stockholm

About CALT

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.